Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Preferred Stock Liabilities (2016 - 2019)

United Therapeutics' Preferred Stock Liabilities history spans 8 years, with the latest figure at $8.4 million for Q2 2019.

  • On a quarterly basis, Preferred Stock Liabilities fell 56.25% to $8.4 million in Q2 2019 year-over-year; TTM through Jun 2019 was $8.4 million, a 56.25% decrease, with the full-year FY2018 number at $19.2 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities hit $8.4 million in Q2 2019 for United Therapeutics, down from $19.2 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for UTHR hit a ceiling of $20.4 million in Q1 2015 and a floor of $8.4 million in Q2 2019.
  • Historically, Preferred Stock Liabilities has averaged $15.2 million across 5 years, with a median of $16.1 million in 2015.
  • Biggest five-year swings in Preferred Stock Liabilities: plummeted 66.6% in 2015 and later skyrocketed 76.15% in 2017.
  • Tracing UTHR's Preferred Stock Liabilities over 5 years: stood at $11.1 million in 2015, then fell by 1.8% to $10.9 million in 2016, then skyrocketed by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then crashed by 56.25% to $8.4 million in 2019.
  • Business Quant data shows Preferred Stock Liabilities for UTHR at $8.4 million in Q2 2019, $19.2 million in Q1 2019, and $19.2 million in Q4 2018.